Skip to main content
Premium Trial:

Request an Annual Quote

Roche Epstein-Barr Virus Quantitative Test Receives FDA Clearance

NEW YORK – Roche announced Wednesday its Cobas Epstein-Barr Virus test was authorized for use by the US Food and Drug Administration.

The quantitative test uses dual target technology to help clinicians monitor transplant patients who are at risk of complications from infections or reactivations of the virus. The PCR viral load test runs on Roche's Cobas 6800 and Cobas 8800 Systems and can be run simultaneously with other virology tests, the company said. It has been calibrated to the World Health Organization International Standard, meaning results are reported in international measures. The test's limit of detection is 18.8 IU per milliliter. 

Roche's test previously received breakthrough device designation from the FDA and obtained CE marking last year. 

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.